Quantcast
Last updated on April 16, 2014 at 11:32 EDT

Latest Donor lymphocyte infusion Stories

2013-08-08 11:00:32

Researchers from Indiana University, the University of Michigan, the Fred Hutchinson Cancer Research Center and the Dana-Farber Cancer Institute have identified and validated a biomarker accessible in blood tests that could be used to predict which stem cell transplant patients are at highest risk for a potentially fatal immune response called graft-versus-host disease. Although transplant specialists have been able to reduce its impact, graft-versus-host disease remains a leading cause of...

2013-07-19 12:24:39

Immunovative Therapies Mirror EffectTM is a unique cancer treatment based on immune system manipulation. Immunovative Therapies says that this treatment creates the tumor-killing effect of bone marrow transplant without the toxic side effects. Immunovative Therapies, using this method, may create a whole new industry of medicine. NEW YORK, July 19, 2013 /PRNewswire-iReach/ -- Dr. Michael Har-Noy, founder and CEO of Immunovative Therapies Ltd, a biotech company in Israel, describes a...

2012-12-10 16:43:16

First study in humans shows promise for preventing graft-versus-host disease following bone marrow transplant A new class of drugs reduced the risk of patients contracting a serious and often deadly side effect of lifesaving bone marrow transplant treatments, according to a study from researchers at the University of Michigan Comprehensive Cancer Center. The study, the first to test this treatment in people, combined the drug vorinostat with standard medications given after transplant,...

2011-11-02 16:00:00

HOUSTON, Nov. 2, 2011 /PRNewswire/ -- Bellicum Pharmaceuticals, Inc. today announced publication in The New England Journal of Medicine of clinical results using a new therapy that demonstrated rapid and complete reversal of graft-versus-host disease (GVHD). The paper, Inducible Apoptosis as a Safety Switch for Adoptive Cell Therapy, reports on the use of Bellicum's CaspaCIDe(TM) technology to eliminate donor T cells causing GVHD, a serious and sometimes fatal complication of allogeneic...

2010-12-21 07:00:00

HOUSTON, Dec. 21, 2010 /PRNewswire/ -- Bellicum Pharmaceuticals, Inc. today announced $3 million in Convertible Note funding. The new funds will be used to prepare for Phase II trials of BPX-101, the company's DeCIDe(TM) vaccine for metastatic castrate resistant prostate cancer (mCRPC), and CaspaCIDe(TM), a cell therapy safety switch under initial development in the hematopoietic stem cell therapy (HSCT) setting. The new funding brings the total raised to date to $11.5 million, including...